Transcatheter Valve-in-Valve and Iatrogenic ASD Closure for Tricuspid Thrombosis in Heparin-Induced Thrombocytopenia

经导管瓣中瓣封堵术和医源性房间隔缺损封堵术治疗肝素诱导的血小板减少症合并三尖瓣血栓形成

阅读:2

Abstract

BACKGROUND: Early bioprosthetic valve thrombosis is a life-threatening complication, and hypercoagulable states such as heparin-induced thrombocytopenia (HIT) can contribute to the formation of thrombi. CASE SUMMARY: A 67-year-old woman with a prior history of HIT and surgical replacement of mitral and tricuspid valves presented with shortness of breath. Transthoracic echocardiography showed an atrial septal defect with right-to-left shunt and thickened tricuspid valve leaflets. Intraoperative transesophageal echocardiography revealed a severe thrombotic bioprosthetic tricuspid valve. She underwent successful transcatheter tricuspid valve-in-valve (TTViV) and atrial septic device closure. DISCUSSION: TTViV is a critical option for patients presenting with early tricuspid valve thrombosis due to HIT. Increased right atrial pressure from tricuspid thrombosis can result in dehiscence of the interatrial sutures, leading to a hemodynamically significant shunt and necessitating its closure. TAKE-HOME MESSAGES: HIT is a prothrombotic state that can lead to early valve thrombosis. TTViV offers an effective treatment option for high-surgical risk patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。